---
title: "Eloxx Pharmaceuticals lacks funds for auditor review"
url: "https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-08-14"
section: "Distress"
tickers: "NASDAQ:ELOX"
source: "https://www.sec.gov/Archives/edgar/data/1035354/000110465925078543/tm2523390d1_nt10q.htm"
summary: "The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going conc"
---

By the aibio.space news desk.

Sources

- [Eloxx Pharmaceuticals, Inc. NT 10-Q (2025-08-14)](https://www.sec.gov/Archives/edgar/data/1035354/000110465925078543/tm2523390d1_nt10q.htm)

[ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)

2025-08-14

# Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash

Tickers [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)

The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern.

## Key facts

- **Company**: Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX)

- **News type**: Distress

- **Primary source**: [Eloxx Pharmaceuticals, Inc. NT 10-Q (2025-08-14)](https://www.sec.gov/Archives/edgar/data/1035354/000110465925078543/tm2523390d1_nt10q.htm)

*The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Eloxx Pharmaceuticals, Inc. ([ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)) said it cannot file its quarterly report for the period ended June 30, 2025 on time because it lacks the money to engage its independent accounting firm.

In a [late filing notice dated August 14, 2025](https://www.sec.gov/Archives/edgar/data/1035354/000110465925078543/tm2523390d1_nt10q.htm), the Arlington, Massachusetts company said it was unable to allocate the financial resources needed to have its auditor audit its financial statements for the years ended December 31, 2024 and 2023. It said those financial constraints are ongoing, so it cannot have the firm review its second quarter statements either.

Eloxx listed the periodic reports it has not filed, including its annual reports on Form 10-K for the fiscal years ended December 31, 2023 and December 31, 2024 and its quarterly report for the quarter ended March 31, 2025.

The company expects to report cash and cash equivalents of $0.6 million as of June 30, 2025, compared with $0.4 million as of March 31, 2024 and $4.8 million as of September 30, 2023. It anticipates a significant increase in its net loss for the three months ended June 30, 2025.

Management expects to disclose substantial doubt about the company's ability to continue as a going concern. That is an accounting warning that a company may not be able to keep operating. Eloxx said it does not have enough cash to support planned operations for at least 12 months.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ELOX

Eloxx Pharmaceuticals, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eloxx Pharmaceuticals lacks funds for auditor review", 2025-08-14, https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/